Comment on FR Doc # 2012-30531

This is a Comment on the Drug Enforcement Administration (DEA) Proposed Rule: Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV

For related information, Open Docket Folder  Docket folder icon


This process took six months – time the drug could have been available to begin treating the obesity epidemic. I personally know many people who desparately need a solution to their obesity problem and are being adversely impacted by the unnecessary delays in brining this drug to market.

Although Arena Pharmaceuticals, the company that developed lorcaserin, spent over $1 billion bringing it through approval, they have been unable to sell the drug while they waited six months for this classification decision.

There is no legitimate reason to classify lorcaserin in any higher level of the Schedule, and I suggest that any comments urging that position have probably been submitted by competitors or hedge funds either invested in competitors or short shares of Arena Pharmaceuticals.

Please limit the period during which you review these comments to two weeks, then confirm your decision and make the Schedule IV decision effective immediately, so that the drug can come to market without any further delay.
Comment Period Closed
Jan 18 2013, at 11:59 PM ET
ID: DEA-2012-0007-0024
Tracking Number: 1jw-82s2-ps1x

Document Information

Date Posted: Jan 3, 2013
RIN: Not Assigned
Show More Details  

Submitter Information

Submitter Name: David Kistler